Orange Book product · Generic (ANDA)
VORICONAZOLE
VORICONAZOLE
At a glance
May 09, 2022
Approved
Generic (ANDA)
Application
AP
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
May 09, 2022
4 yr 2 mo ago
Today
Pharmaceutical detail
Active ingredient
VORICONAZOLE
Strength
200MG/VIAL
Dosage form
POWDER
Route
INTRAVENOUS
TE code
AP
Application
ANDA 214516
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of VORICONAZOLE
- 2017VORICONAZOLEBrand (NDA)
NDA 208562 · HIKMA
- 2003VFENDBrand (NDA)
NDA 021630 · PF PRISM CV
- 2002VFENDBrand (NDA)
NDA 021267 · PF PRISM CV
- 2002VFENDBrand (NDA)
NDA 021266 · PF PRISM CV
- 2026VORICONAZOLEGeneric (ANDA)
ANDA 220078 · ZHEJIANG NOVUS
- 2025VORICONAZOLEGeneric (ANDA)
ANDA 220043 · HAINAN POLY PHARM
- 2025VORICONAZOLEGeneric (ANDA)
ANDA 211598 · HETERO LABS LTD V
- 2024VORICONAZOLEGeneric (ANDA)
ANDA 218533 · ASPIRO
- 2024VORICONAZOLEGeneric (ANDA)
ANDA 216805 · ZHEJIANG POLY PHARM
- 2023VORICONAZOLEGeneric (ANDA)
ANDA 211264 · UBI
- 2023VORICONAZOLEGeneric (ANDA)
ANDA 212162 · EUGIA PHARMA
- 2022VORICONAZOLEGeneric (ANDA)
ANDA 210849 · PHARMOBEDIENT
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
